• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Movantik Chosen as Preferred Brand for Some Blue Cross Plans

News
Article

The therapy for opioid-induced constipation has no restrictions on an unidentified national formulary that serves these Blues plans.

RedHill Biopharma, a specialty biopharmaceutical company in Raleigh, N.C., has received Preferred Brand status on a unidentified national formulary that serves some Blue Cross plans for Movantik (naloxegol), a treatment for opioid-induced constipation. The coverage started on July 1, 2021.

“This important new listing as an unrestricted preferred brand strengthens Movantik’s leadership position and now means that over 30 million more Americans will have access to Movantik,” Rick Scruggs, RedHill’s chief commercial officer, said in a statement.

Company officials said Movantik’s total commercial coverage now extends to 152 million American patients’ lives.

The FDA approved Movantik in September 2014. RedHill acquired global marketing rights (except in Europe and Canada) to Movantik from AstraZeneca in April 2020.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.